+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication

Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication

Zhonghua Shen Jing Jing Shen Ke Za Zhi 17(5): 273-277

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 042497527

Download citation: RISBibTeXText

PMID: 6085683

Related references

A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. Psychiatry Research 4(1): 95, 1981

Platelet monoamine oxidase activity in patients with chronic schizophrenic illnesses untreated by neuroleptic drugs. British Journal of Clinical Pharmacology 2(4): 380p, 1975

Plasma levels of beta-endorphin under chronic neuroleptic treatment in schizophrenic patients: failure of naloxone to counteract curative effects of neuroleptic drugs. Advances in Biochemical Psychopharmacology 22: 489-502, 1980

Platelet monoamine oxidase activity in neuroleptic-naive schizophrenic patients: lack of influence of chronic perphenazine treatment. Clinical Neuropharmacology 17(1): 83-88, 1994

CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine 15(2): 335-340, 1985

The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy. American Journal of Psychiatry 138(2): 184-188, 1981

Decrease of CSF dopamine, its metabolites and noradrenalin after withdrawal of chronic neuroleptic treatment in schizophrenic patients. Psychiatry Research 12(2): 177-178, 1984

Effect of probenecid on the levels of monoamine metabolites in the rat brain. Acta Pharmacol Toxicol 25(1): 18-23, 1967

CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Psychiatry Research 19(2): 93, 1986

Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. International Clinical Psychopharmacology 17(1): 41-44, 2002

Intravenous probenecid loading. Effects on plasma and cerebrospinal fluid probenecid levels and on monoamine metabolites in cerebrospinal fluid. Neurology 26(10): 992-996, 1976

Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients. Archives of General Psychiatry 36(5): 579-584, 1979

Steady-state levels of probenecid and their relation to acid monoamine metabolites in human cerebrospinal fluid. Psychopharmacologia 25(1): 96-100, 1972

Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clinical Neuropharmacology 21(4): 245-250, 1998

Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. Journal of Psychiatric Research 41(8): 625-634, 2007